Cunningham panel – Moleculera Labs – Spain

El Panel Cunningham ayuda a los médicos a identificar si los síntomas neurológicos y / o psiquiátricos de un paciente pueden deberse a una encefalitis de los ganglios basales (BGE) desencadenada por una infección, que incluye síndromes neuropsiquiátricos autoinmunes como PANS / PANDAS. The symptoms of BGE can mimic various mental illnesses. The Cunningham Panel measures circulating levels of autoantibodies that attack receptors in the brain, as well as autoantibodies that stimulate neurotransmitter production in the basal ganglia. These interactions have the potential to disrupt neural functioning and can affect movement, behavior, and cognition. The results of these tests can support a physician's clinical diagnosis with laboratory evidence of an underlying autoimmune dysfunction and help the physician determine an appropriate treatment regimen.

The Cunningham Panel™ is a metabolic test, laboratory results represent values at the time the patient's blood was drawn, which may vary over time, with treatment, and in conjunction with the presence or absence of symptoms. This panel is composed of 5 tests: Anti-Dopamine D1 Receptor, Anti-Dopamine D2L Receptor, Anti-Lysoganglioside-GM1, Anti-Tubulin and Calcium/calmodulin-dependent protein kinase II (CaMKII). The first four of the tests measure the levels of circulating autoantibodies in the serum that are directed against, bind to, or block specific neural targets in the brain. Each of these autoantibody targets (dopamine D1 and D2L receptors, lysoganglioside-GM1, and tubulin) have been associated with the presence of various neurological and/or psychiatric symptoms. The last one, the CaMKII test, is a cell stimulation assay. It measures the ability of a patient's autoantibodies to stimulate the CaMKII enzyme in human brain cells. CaMKII is involved in upregulating the production of neurotransmitters: dopamine, epinephrine, and norepinephrine, and elevated levels of CaMKII activity correlate with certain adrenergic symptoms (these include nerve cells in which certain neurotransmitters are activated), as well as the likelihood of an active infection or reinfection. When autoantibodies bind to or block these targets, they can disrupt normal neuronal functioning, leading to neuropsychiatric symptoms. Elevated levels in one or more of these tests indicate that a person's neuropsychiatric symptoms may be due to a treatable autoimmune disorder (caused by an infection), rather than a classic neurological or psychiatric illness.

The Cunningham Panel™ is unique and is based on more than two decades of research. It is offered exclusively through Moleculera Labs, Inc. and has been used by physicians around the world.

PEER REVIEWED JOURNAL ARTICLES

Neuropsychiatric disorders/PANS and PANDAS

There are numerous studies documenting the connection between abnormal immune system activity and neuropsychiatric diseases. Below is a list of peer-reviewed journal articles from world-leading investigators investigating infection-induced autoimmune neurological disorders, including PANS and PANDAS.